SPMED Co., Ltd., a specialist in preclinical CRO services, has been officially recognized as the "2025 Best CRO" by Daewoong Pharmaceutical’s New Drug Center.
Since 2024, the Daewoong Pharmaceutical New Drug Center has conducted an annual evaluation of its drug development partners based on Expertise, Collaboration, and Contribution to Research Results.
SPMED was honored with this award in recognition of its exceptional research integrity and seamless collaborative efforts throughout a wide range of drug development projects over the past year.
■ Excellence in Preclinical Efficacy and Strategic Collaboration
SPMED successfully conducted efficacy evaluations for Daewoong Pharmaceutical’s key pipelines, specifically focusing on autoimmune disease treatment candidates.
The company's specialized expertise and consistent quality management "spanning from the initial study design to final data interpretation" have been evaluated as having played a pivotal role in the preclinical stages of Daewoong’s drug development pipeline.
Researchers at the Daewoong Pharmaceutical New Drug Center explained the selection, stating, "SPMED demonstrated a high level of professionalism and responsibility in challenging preclinical efficacy, metabolism, and analytical evaluations.
They have left a lasting impression as a deeply reliable partner."
■ Global Leap through Specialized ADME Solutions
This recognition is highly significant as it represents a tangible contribution to a partner’s success in drug development, going beyond mere contract performance.
SPMED is committed to advancing as a world-class CRO by leveraging its differentiated research capabilities and specialized preclinical models in fields such as autoimmunity and immuno-oncology.
Looking toward 2026, SPMED aims for rapid growth by strategically expanding its preclinical evaluation services specialized in the ADME (Absorption, Distribution, Metabolism, and Excretion) field.
Through this, the company will continue to provide integrated research solutions and infrastructure to support precise decision-making for domestic and international pharmaceutical and biotech firms.
